Logo

BMS Receives EMA’s Validation for Opdivo (nivolumab) in Combination with Chemotherapy for the Treatment of Urothelial Carcinoma

Share this
Bristol Myers Squibb

BMS Receives EMA’s Validation for Opdivo (nivolumab) in Combination with Chemotherapy for the Treatment of Urothelial Carcinoma

Shots:

  • The EMA accepted BMS' type II variation application for Opdivo + cisplatin-based CT as 1L treatment of adult patients with unresectable/metastatic urothelial carcinoma based on the results from the P-III (CheckMate-901) study 
  • The P-III (CheckMate-901) clinical trial evaluates the safety & efficacy of Opdivo (360mg, Q3W) + cisplatin-based CT followed by Opdivo monotx. (480mg, Q4W) vs SoC CT in patients (n=608) with urothelial carcinoma. The company is currently evaluating Opdivo + Yervoy vs SoC CT for the same indication
  • The P-III efficacy results, presented at ESMO’23, showed improved OS and PFS as evaluated by BICR. Safety profiles were tolerable and consistent

Ref: BMS | Image: BMS

Related News:- BMS Reports Three-Year Follow-Up Results from Exploratory Analyses of P-III Trial (CheckMate -816) for Opdivo to Treat Resectable Non-Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions